Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 15;9:7430. doi: 10.1038/s41598-019-43834-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Adenosine and Adenosine functionalized nanoparticles stimulate cAMP accumulation. (A) Adenosine and PLA-PEG2000-3,4-OH-adenosine (PEG2000-Ado) but not PEG400-Ado or PEG2000-PLA-5′-OH-adenosine or PEG2000-PLA-6-NH-adenosine particles stimulate a significant increase in cellular content of cAMP as compared to vehicle in the RAW 264.7 cell line. (B) Adenosine A2A and A2B antagonists reverse the effect of adenosine functionalized nanoparticles on cAMP accumulation. Co-treatment with A2AR antagonist ZM241385, the A2BR antagonist PSB1115 and the poorly selective A1R/A2R antagonist DPCPX significantly reduced the PEG2000-Ado effect on cAMP production. Data are expressed as % control cAMP content and each data point shown represents results of experiments carried out on a single day in duplicate. (*p < 0.05; **p < 0.01; n = 3–5).